Study details
Enrolling now
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis
Eli Lilly and Company
NCT IDNCT07186101ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
252
Study length
about 3.4 years
Ages
18–80
Locations
41 sites in AZ, CA, CO +16
About this study
Researchers are testing whether LY4268989, given with mirikizumab, is more effective than mirikizumab alone for adults with moderately to severely active ulcerative colitis. The trial will last about 118 weeks and involve approximately 252 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take LY4268989
- 2.Take LY4268989 Placebo
- 3.Take Mirikizumab
PhasePhase 2
DrugMirikizumab
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low7%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
mirikizumab
Body systems
Gastroenterology